Foundation Medicine, Inc. (FMI) CFO Jason Ryan Sells 3,154 Shares
Foundation Medicine, Inc. (NASDAQ:FMI) CFO Jason Ryan sold 3,154 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $38.80, for a total transaction of $122,375.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Jason Ryan also recently made the following trade(s):
- On Thursday, July 13th, Jason Ryan sold 5,084 shares of Foundation Medicine stock. The shares were sold at an average price of $39.77, for a total transaction of $202,190.68.
- On Thursday, July 6th, Jason Ryan sold 6,683 shares of Foundation Medicine stock. The shares were sold at an average price of $38.84, for a total transaction of $259,567.72.
Shares of Foundation Medicine, Inc. (FMI) traded up 3.39% during trading on Wednesday, hitting $41.15. 141,747 shares of the stock were exchanged. Foundation Medicine, Inc. has a 52 week low of $17.10 and a 52 week high of $43.15. The firm’s market capitalization is $1.48 billion. The stock’s 50 day moving average price is $39.20 and its 200 day moving average price is $37.27.
Foundation Medicine (NASDAQ:FMI) last announced its quarterly earnings data on Tuesday, August 1st. The company reported ($1.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.08) by ($0.16). Foundation Medicine had a negative net margin of 131.79% and a negative return on equity of 109.63%. The business had revenue of $35.00 million during the quarter, compared to analysts’ expectations of $34.94 million. During the same period last year, the company posted ($0.84) EPS. Foundation Medicine’s revenue for the quarter was up 23.9% on a year-over-year basis. On average, equities analysts predict that Foundation Medicine, Inc. will post ($4.67) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Foundation Medicine, Inc. (FMI) CFO Jason Ryan Sells 3,154 Shares” was originally reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/10/04/foundation-medicine-inc-fmi-cfo-jason-ryan-sells-3154-shares.html.
Several institutional investors have recently made changes to their positions in FMI. Lord Abbett & CO. LLC boosted its stake in shares of Foundation Medicine by 146.0% in the 2nd quarter. Lord Abbett & CO. LLC now owns 579,225 shares of the company’s stock valued at $23,024,000 after purchasing an additional 343,770 shares in the last quarter. State Street Corp boosted its stake in shares of Foundation Medicine by 124.2% in the 2nd quarter. State Street Corp now owns 526,775 shares of the company’s stock valued at $20,947,000 after purchasing an additional 291,815 shares in the last quarter. Alliancebernstein L.P. boosted its stake in shares of Foundation Medicine by 38.7% in the 1st quarter. Alliancebernstein L.P. now owns 788,860 shares of the company’s stock valued at $25,441,000 after purchasing an additional 220,236 shares in the last quarter. Pier Capital LLC purchased a new stake in shares of Foundation Medicine in the 2nd quarter valued at $6,126,000. Finally, Adalta Capital Management LLC purchased a new stake in shares of Foundation Medicine in the 1st quarter valued at $4,056,000. 31.84% of the stock is owned by institutional investors.
A number of analysts have weighed in on FMI shares. BidaskClub upgraded shares of Foundation Medicine from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 24th. Zacks Investment Research lowered shares of Foundation Medicine from a “hold” rating to a “sell” rating in a report on Tuesday. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $35.00.
Foundation Medicine Company Profile
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.